GnT-IVB Inhibitors
Chemical inhibitors of GnT-IVB function primarily by disrupting the enzyme's substrate availability, which is essential for its glycosyltransferase activity. Swainsonine, for instance, impedes the function of mannosidase II, leading to an accumulation of misfolded glycoproteins. This disruption hinders the formation of substrate glycoproteins that GnT-IVB typically modifies. Similarly, deoxynojirimycin and castanospermine, both glucosidase inhibitors, thwart the proper folding and assembly of N-linked glycoproteins, which are crucial substrates for GnT-IVB. By impeding the processing of N-glycans, these inhibitors limit the substrate availability for GnT-IVB, thereby indirectly inhibiting its activity. The prodrug celgosivir, a derivative of castanospermine, and salacinol both inhibit alpha-glucosidases, which leads to improper glycoprotein folding and reduced substrate availability for GnT-IVB.
Other inhibitors, like miglitol and voglibose, also target alpha-glucosidase enzymes involved in trimming glycan structures on glycoproteins, further reducing the substrate pool for GnT-IVB. PUGNAc's inhibition of O-GlcNAcase can increase O-GlcNAc modification of proteins, which may interfere with N-glycan processing necessary for GnT-IVB substrates. Kifunensine, a mannosidase I inhibitor, prevents the processing of oligosaccharides on glycoproteins, leading to a decrease in complex N-glycans that GnT-IVB relies on for its function. Nojirimycin, with a similar inhibitory mechanism, impedes the maturation of N-glycans. Lastly, isofagomine, by inhibiting glucosidase, hinders the appropriate folding and processing of glycoproteins, thus diminishing the efficacy of GnT-IVB by reducing the available pool of substrate glycoproteins. Collectively, these chemical inhibitors target different aspects of glycoprotein processing and maturation, which are critical steps in the production of GnT-IVB substrates, hence effectively inhibiting the activity of the enzyme.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $135.00 $246.00 $619.00 $799.00 $1796.00 | 6 | |
Swainsonine inhibits mannosidase II, which can lead to the accumulation of misfolded glycoproteins and thereby inhibit the function of GnT-IVB by preventing the proper formation of substrate glycoproteins that GnT-IVB would normally act upon. | ||||||
Deoxynojirimycin | 19130-96-2 | sc-201369 sc-201369A | 1 mg 5 mg | $72.00 $142.00 | ||
As a glucosidase inhibitor, deoxynojirimycin can prevent the proper folding and assembly of N-linked glycoproteins, which are the substrates for GnT-IVB, thereby inhibiting the function of GnT-IVB. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $180.00 $620.00 | 10 | |
Castanospermine is a glucosidase inhibitor which can disrupt the processing of N-glycans, thus impeding the substrate availability for GnT-IVB and indirectly inhibiting its enzymatic activity. | ||||||
Deoxymannojirimycin hydrochloride | 84444-90-6 | sc-201360 sc-201360A | 1 mg 5 mg | $93.00 $239.00 | 2 | |
By inhibiting the processing enzymes involved in glycan synthesis, 1-deoxymannojirimycin can reduce the production of complex N-glycans, which are necessary substrates for GnT-IVB, thus indirectly inhibiting its function. | ||||||
Celgosivir | 121104-96-9 | sc-488385 sc-488385A sc-488385B | 5 mg 25 mg 100 mg | $525.00 $902.00 $2700.00 | ||
Celgosivir, a prodrug of castanospermine, inhibits alpha-glucosidases I and II leading to improper glycoprotein folding and reduced availability of mature glycoproteins for GnT-IVB, thereby inhibiting its activity. | ||||||
Miglitol | 72432-03-2 | sc-221943 | 10 mg | $158.00 | 1 | |
Miglitol inhibits alpha-glucosidase enzymes which are involved in the trimming of glycan structures on glycoproteins, limiting the substrate availability for GnT-IVB and consequently its activity. | ||||||
Voglibose | 83480-29-9 | sc-204384 sc-204384A | 10 mg 50 mg | $194.00 $668.00 | ||
Voglibose is another alpha-glucosidase inhibitor that leads to improper glycan processing, potentially limiting the substrates available for GnT-IVB's glycosyltransferase function. | ||||||
(Z)-Pugnac | 132489-69-1 | sc-204415A sc-204415 | 5 mg 10 mg | $220.00 $373.00 | 3 | |
PUGNAc inhibits O-GlcNAcase, which could increase O-GlcNAc modification of proteins, potentially interfering with N-glycan processing and substrates for GnT-IVB, thus indirectly inhibiting its activity. | ||||||
Kifunensine | 109944-15-2 | sc-201364 sc-201364A sc-201364B sc-201364C | 1 mg 5 mg 10 mg 100 mg | $132.00 $529.00 $1005.00 $6125.00 | 25 | |
Kifunensine is a mannosidase I inhibitor that inhibits the processing of oligosaccharides on glycoproteins, which could lead to a reduction in complex N-glycans that GnT-IVB utilizes, thereby inhibiting its activity. | ||||||
Isofagomine D-Tartrate | 957230-65-8 | sc-207767 sc-207767A sc-207767C sc-207767B | 5 mg 10 mg 50 mg 25 mg | $379.00 $710.00 $1975.00 $1199.00 | ||
Isofagomine, a glucosidase inhibitor, could hinder the proper folding and processing of glycoproteins, thus indirectly reducing the efficiency of GnT-IVB by diminishing the pool of substrate glycoproteins. | ||||||